PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Chemoprevention of Oral Premalignant Lesions
Phase 2
Completed
- Conditions
- Precancerous Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00036283
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Phase 3
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00036270
- Locations
- 🇺🇸
Pfizer Investigational Site, Vancouver, Washington, United States
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
Phase 3
Terminated
- Conditions
- Parkinson Disease
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2007-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 984
- Registration Number
- NCT00036205
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00036140
- Locations
- 🇺🇸
Research Center, Marshfield, Wisconsin, United States
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
Phase 3
Completed
- Conditions
- Bacterial Infections
- First Posted Date
- 2002-05-07
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00035854
- Locations
- 🇺🇸
Research Center, Austin, Texas, United States
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00035425
- Locations
Pfizer Investigational Site
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
Phase 4
Completed
- Conditions
- Community-Acquired Pneumonia (CAP)
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00035347
- Locations
- 🇪🇸
Pfizer Investigational Site, Tarrasa, Cataluna, Spain
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell LungLung Neoplasms
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00034957
- Locations
- 🇺🇸
Research Center, Dallas, Texas, United States
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
Phase 3
Completed
- Conditions
- Pneumonia, PneumococcalCommunity Acquired InfectionsGram-positive Bacterial Infections
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00035269
- Locations
- 🇨🇳
Research Center, Taoyuan, Taiwan
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
Phase 2
Completed
- Conditions
- Colorectal NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 172
- Registration Number
- NCT00034827
- Locations
- 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath